Neomorph and Novo Nordisk collaborate on molecular glue degraders for cardiometabolic and rare diseases
Feb. 27, 2024
Neomorph Inc. has entered into a collaboration and licensing agreement with Novo Nordisk A/S to discover, develop and commercialize molecular glue degraders.
